Tetrahydrocannabivarin THCV Clinical Research
![THCV Clinical Research](https://covalentcbd.com/wp-content/uploads/2022/02/Cannabinoid-Banner-THCV.png)
NOTABLE THCV SCIENCE:
Δ9-Tetrahydrocannabivarin THCV: a commentary on potential therapeutic benefit for the management of obesity and diabetes
Amos Abioye, Oladapo Ayodele, Aleksandra Marinkovic, Risha Patidar, Adeola Akinwekomi, Adekunle Sanyaolu | January 31, 2020 | Journal of Cannabis Research | Full Text ![THCV Type 2 Diabetes](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett, E. Louise Thomas, Colin Stott, Jimmy D. Bell, Saoirse E. O’Sullivan, Garry D. Tan | September 13, 2016 | Diabetes CareVolume 39, Issue 10 | Full Text ![THCV Food Aversion](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers
Luke Tudge, MSc, Clare Williams, BSc, Philip J. Cowen, MD, FRCPsych, Ciara McCabe, PhD | April, 2015 | International Journal of Neuropsychopharmacology, 2015, 1–9 | Full Text ![Delta-9 THCV insulin sensitivity](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
The cannabinoid Δ9-tetrahydrocannabivarin THCV ameliorates insulin sensitivity in two mouse models of obesity
E T Wargent, M S Zaibi, C Silvestri, D C Hislop, C J Stocker, C G Stott, G W Guy, M Duncan, V Di Marzo, M A Cawthorne | May 2013 | Nutrition & Diabetes | Full Text ![THCV Fasting Mice](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice
Gernot Riedel, Paola Fadda, Susan McKillop-Smith, Roger G Pertwee, Bettina Platt, Lianne Robinson | April 2009 | British Journal of Pharmacology | Full Text ![THCV Pharmacology](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
R G Pertwee | January 2008 | British Journal of Pharmacology | Full Text ![THCV cannabinoid](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo
R G Pertwe, A Thomas, L A Stevenson, R A Ross, S A Varvel, A H Lichtman, B R Martin, R K Razdan | January 22, 2007 | British Journal of Pharmacology | Full Text ![Delta-9 THCV](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)
Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist
Adèle Thomas, Lesley A Stevenson, Kerrie N Wease, Martin R Price, Gemma Baillie, Ruth A Ross, Roger G Pertwee1 | October 3, 2005 | British Journal of Pharmacology | Full Text ![THCV Diabetes](https://covalentcbd.com/wp-content/uploads/2022/02/Divider-41.png)